![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CLEC2L |
Gene summary for CLEC2L |
![]() |
Gene information | Species | Human | Gene symbol | CLEC2L | Gene ID | 154790 |
Gene name | C-type lectin domain family 2 member L | |
Gene Alias | CLEC2L | |
Cytomap | 7q34 | |
Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | P0C7M8 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
154790 | CLEC2L | S014 | Human | Liver | HCC | 1.19e-50 | 1.37e+00 | 0.2254 |
154790 | CLEC2L | S015 | Human | Liver | HCC | 2.68e-22 | 7.87e-01 | 0.2375 |
154790 | CLEC2L | S016 | Human | Liver | HCC | 1.35e-41 | 9.37e-01 | 0.2243 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CLEC2L | SNV | Missense_Mutation | c.238G>A | p.Ala80Thr | p.A80T | P0C7M8 | protein_coding | tolerated(0.09) | benign(0.011) | TCGA-EA-A3HS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
CLEC2L | SNV | Missense_Mutation | rs768735887 | c.568G>A | p.Val190Met | p.V190M | P0C7M8 | protein_coding | deleterious(0.01) | possibly_damaging(0.647) | TCGA-F4-6856-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Ancillary | leucovorin | CR |
CLEC2L | SNV | Missense_Mutation | c.181G>A | p.Ala61Thr | p.A61T | P0C7M8 | protein_coding | tolerated(0.06) | benign(0.057) | TCGA-WS-AB45-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
CLEC2L | SNV | Missense_Mutation | c.406N>C | p.Ala136Pro | p.A136P | P0C7M8 | protein_coding | deleterious(0.01) | possibly_damaging(0.752) | TCGA-CL-5918-01 | Colorectum | rectum adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
CLEC2L | SNV | Missense_Mutation | c.610N>T | p.Arg204Trp | p.R204W | P0C7M8 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-AX-A1C5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | SD | |
CLEC2L | SNV | Missense_Mutation | c.238N>A | p.Ala80Thr | p.A80T | P0C7M8 | protein_coding | tolerated(0.09) | benign(0.011) | TCGA-D1-A17R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
CLEC2L | SNV | Missense_Mutation | novel | c.358N>A | p.Asp120Asn | p.D120N | P0C7M8 | protein_coding | tolerated(0.8) | benign(0.127) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CLEC2L | SNV | Missense_Mutation | c.357N>T | p.Arg119Ser | p.R119S | P0C7M8 | protein_coding | tolerated(0.32) | benign(0.438) | TCGA-44-7669-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | alimta | PD | |
CLEC2L | SNV | Missense_Mutation | novel | c.347N>T | p.Glu116Val | p.E116V | P0C7M8 | protein_coding | deleterious(0) | benign(0.354) | TCGA-55-8621-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CLEC2L | SNV | Missense_Mutation | novel | c.614N>T | p.Pro205Leu | p.P205L | P0C7M8 | protein_coding | tolerated(0.36) | possibly_damaging(0.684) | TCGA-VQ-A91D-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | fluorouracil | PD |
Page: 1 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |